Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    113
    ...
ATC Name B/G Ingredients Dosage Form Price
C10AA07 ROVASTIN G Rosuvastatin (calcium) - 20mg 20mg Tablet 560,574 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 749,058 L.L
C10AA07 SINLIP G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 563,070 L.L
G04BE08 AMOS G Tadalafil - 20mg 20mg Film, orodispersible 2,175,745 L.L
C10AA07 SUPERSTAT G Rosuvastatin (calcium) - 20mg 20mg Tablet, coated 517,379 L.L
C10AA07 UBSATOR-CA G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 499,142 L.L
G04BE09 LEVITRA B Vardenafil (HCl) - 20mg 20mg Tablet, film coated 2,660,808 L.L
G04BE09 LEVIDOR G Vardenafil (HCl) - 20mg 20mg Tablet 774,053 L.L
A02BC08 VONSECA G Vonoprazan - 20mg 20mg Tablet, film coated 1,706,680 L.L
G04BE09 VARI G Vardenafil (HCl) - 20mg 20mg Tablet 1,554,932 L.L
L01AX03 TEMOZOLOMIDE ACCORD G Temozolomide - 20mg 20mg Capsule, hard L.L
D10BA01 ROACCUTANE B Isotretinoin - 20mg 20mg Capsule 2,354,412 L.L
D10BA01 A-CNOTREN G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,526,524 L.L
D10BA01 CONTRACNE ISOTRETINOINE G Isotretinoin - 20mg 20mg Capsule, soft 1,521,230 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 888,280 L.L
D10BA01 CURACNE G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,603,204 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 954,128 L.L
D10BA01 CURACNE G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,603,204 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 954,128 L.L
D10BA01 CURACNE G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,603,204 L.L
A03A SPASMOBROM B Pipethanate Ethobromide - 20mg 20mg Tablet, coated 705,517 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 20mg 20mg Tablet, film coated 667,890 L.L
D10BA01 CURACNE G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,603,204 L.L
C05CX REPARIL B Aescine - 20mg 20mg Tablet, sugar coated 510,660 L.L
M01AC01 PIROXEN DISPERSIBLE G Piroxicam - 20mg 20mg Tablet, dispersible 450,187 L.L
M01AC01 BREXIN B Piroxicam-?-cyclodextrin - 20mg 20mg Tablet, scored 487,815 L.L
M01AC02 REUTENOX G Tenoxicam - 20mg 20mg Tablet, coated 576,508 L.L
C07AB05 KERLONE B Betaxolol HCl - 20mg 20mg Tablet, film coated, scored 575,165 L.L
N02AA01 ACTISKENAN G Morphine sulfate - 20mg 20mg Capsule, immediate release 512,004 L.L
L01EJ01 JAKAVI B Ruxolitinib - 20mg 20mg Tablet 352,121,341 L.L
    ...
    113
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026